295 related articles for article (PubMed ID: 28705007)
1. Pancreas adenocarcinoma: novel therapeutics.
Krantz BA; Yu KH; O'Reilly EM
Chin Clin Oncol; 2017 Jun; 6(3):30. PubMed ID: 28705007
[TBL] [Abstract][Full Text] [Related]
2. [Advances in immunotherapy of pancreatic ductal adenocarcinoma].
Yang JQ; Wei T; Chen YW; Bai XL; Liang TB
Zhonghua Wai Ke Za Zhi; 2017 May; 55(5):396-400. PubMed ID: 28464583
[TBL] [Abstract][Full Text] [Related]
3. Pancreatic ductal adenocarcinoma: Emerging therapeutic strategies.
Osei-Bordom DC; Serifis N; Brown ZJ; Hewitt DB; Lawal G; Sachdeva G; Cloonan DJ; Pawlik TM
Surg Oncol; 2022 Aug; 43():101803. PubMed ID: 35830772
[TBL] [Abstract][Full Text] [Related]
4. Role of targeted immunotherapy for pancreatic ductal adenocarcinoma (PDAC) treatment: An overview.
Panchal K; Sahoo RK; Gupta U; Chaurasiya A
Int Immunopharmacol; 2021 Jun; 95():107508. PubMed ID: 33725635
[TBL] [Abstract][Full Text] [Related]
5. The evolution into personalized therapies in pancreatic ductal adenocarcinoma: challenges and opportunities.
Tesfaye AA; Kamgar M; Azmi A; Philip PA
Expert Rev Anticancer Ther; 2018 Feb; 18(2):131-148. PubMed ID: 29254387
[TBL] [Abstract][Full Text] [Related]
6. Advances in immunotherapy for pancreatic ductal adenocarcinoma.
Miyazawa M; Katsuda M; Kawai M; Hirono S; Okada KI; Kitahata Y; Yamaue H
J Hepatobiliary Pancreat Sci; 2021 May; 28(5):419-430. PubMed ID: 33742512
[TBL] [Abstract][Full Text] [Related]
7. Rational combinations of immunotherapy for pancreatic ductal adenocarcinoma.
Blair AB; Zheng L
Chin Clin Oncol; 2017 Jun; 6(3):31. PubMed ID: 28705008
[TBL] [Abstract][Full Text] [Related]
8. Targeting the metabolism and immune system in pancreatic ductal adenocarcinoma: Insights and future directions.
Bandi DSR; Sarvesh S; Farran B; Nagaraju GP; El-Rayes BF
Cytokine Growth Factor Rev; 2023; 71-72():26-39. PubMed ID: 37407355
[TBL] [Abstract][Full Text] [Related]
9. [Pancreatic ductal adenocarcinoma immune microenvironment and immunotherapy prospects].
Ye C; Zheng L; Yuan CH
Zhonghua Wai Ke Za Zhi; 2019 Jan; 57(1):10-15. PubMed ID: 30612387
[TBL] [Abstract][Full Text] [Related]
10. Perspectives in the treatment of pancreatic adenocarcinoma.
Cid-Arregui A; Juarez V
World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356
[TBL] [Abstract][Full Text] [Related]
11. Tumoral EHF predicts the efficacy of anti-PD1 therapy in pancreatic ductal adenocarcinoma.
Liu J; Jiang W; Zhao K; Wang H; Zhou T; Bai W; Wang X; Zhao T; Huang C; Gao S; Qin T; Yu W; Yang B; Li X; Fu D; Tan W; Yang S; Ren H; Hao J
J Exp Med; 2019 Mar; 216(3):656-673. PubMed ID: 30733283
[TBL] [Abstract][Full Text] [Related]
12. An Immunological Glance on Pancreatic Ductal Adenocarcinoma.
Melzer MK; Arnold F; Stifter K; Zengerling F; Azoitei N; Seufferlein T; Bolenz C; Kleger A
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397303
[TBL] [Abstract][Full Text] [Related]
13. Challenges and Perspectives for Immunotherapy in Adenocarcinoma of the Pancreas: The Cancer Immunity Cycle.
Kieler M; Unseld M; Bianconi D; Prager G
Pancreas; 2018 Feb; 47(2):142-157. PubMed ID: 29346215
[TBL] [Abstract][Full Text] [Related]
14. The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications.
Liu X; Xu J; Zhang B; Liu J; Liang C; Meng Q; Hua J; Yu X; Shi S
Mol Cancer; 2019 Dec; 18(1):184. PubMed ID: 31831007
[TBL] [Abstract][Full Text] [Related]
15. Novel Therapeutics for Pancreatic Adenocarcinoma.
Lowery MA; O'Reilly EM
Hematol Oncol Clin North Am; 2015 Aug; 29(4):777-87. PubMed ID: 26226910
[TBL] [Abstract][Full Text] [Related]
16. Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future.
Christenson ES; Jaffee E; Azad NS
Lancet Oncol; 2020 Mar; 21(3):e135-e145. PubMed ID: 32135117
[TBL] [Abstract][Full Text] [Related]
17. Trials and tribulations of pancreatic cancer immunotherapy.
Principe DR; Korc M; Kamath SD; Munshi HG; Rana A
Cancer Lett; 2021 Apr; 504():1-14. PubMed ID: 33549709
[TBL] [Abstract][Full Text] [Related]
18. Understanding the immune response and the current landscape of immunotherapy in pancreatic cancer.
Ostios-Garcia L; Villamayor J; Garcia-Lorenzo E; Vinal D; Feliu J
World J Gastroenterol; 2021 Oct; 27(40):6775-6793. PubMed ID: 34790007
[TBL] [Abstract][Full Text] [Related]
19. Molecular and metabolic regulation of immunosuppression in metastatic pancreatic ductal adenocarcinoma.
Gautam SK; Batra SK; Jain M
Mol Cancer; 2023 Jul; 22(1):118. PubMed ID: 37488598
[TBL] [Abstract][Full Text] [Related]
20. The tumor microenvironment in pancreatic ductal adenocarcinoma: current perspectives and future directions.
Herting CJ; Karpovsky I; Lesinski GB
Cancer Metastasis Rev; 2021 Sep; 40(3):675-689. PubMed ID: 34591240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
